---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-080409"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2026-07-02T21:01:00+00:00"
generated_at: "2026-07-02T21:04:16.905393+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Iovance updates corporate presentation; guides FY26 revenue $350M-$370M, Q2 $86M-$88M

## Summary
- Q2 2026 revenue guidance of $86M-$88M; FY26 revenue guidance $350M-$370M; ~45% YoY quarterly growth.
- Amtagvi commercial launch: >90 treatment centers, >1,500 patients treated; 5-year durability data: 31.4% ORR, 19.7% OS.
- Lifileucel in NSCLC: 25.6% ORR, mDOR not reached at 25.4 months; Fast Track Designation; potential launch 2H27.
- Soft tissue sarcoma Phase 2 registrational trial to commence 2Q 2026; 50% ORR in early data.
- Cash $319M as of 3/31/26; manufacturing capacity up to 5K patients/year; broad payer coverage.

## SEC filing metadata
- accession: 0001104659-26-080409
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2026-07-02T21:01:00+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465926080409/0001104659-26-080409-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465926080409/tm2618989d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-080409
- JSON: https://secwatch.observer/filing/0001104659-26-080409.json
- Plain text: https://secwatch.observer/filing/0001104659-26-080409.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.